PL2866797T3 - Stabilna, nadająca się do wstrzykiwania kompozycja farmaceutyczna antagonisty receptora neurokininy-1 i sposób jej wytwarzania - Google Patents

Stabilna, nadająca się do wstrzykiwania kompozycja farmaceutyczna antagonisty receptora neurokininy-1 i sposób jej wytwarzania

Info

Publication number
PL2866797T3
PL2866797T3 PL12756353T PL12756353T PL2866797T3 PL 2866797 T3 PL2866797 T3 PL 2866797T3 PL 12756353 T PL12756353 T PL 12756353T PL 12756353 T PL12756353 T PL 12756353T PL 2866797 T3 PL2866797 T3 PL 2866797T3
Authority
PL
Poland
Prior art keywords
neurokinin
preparation
pharmaceutical composition
receptor antagonist
injectable pharmaceutical
Prior art date
Application number
PL12756353T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthimos KOUTRIS
Dimitrios Bikiaris
Sotiria CHATIDOU
Amalia DIAKIDOU
Panagiotis BARMPALEXIS
Louiza KONSTANTI
Katerina MINIOTI
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of PL2866797T3 publication Critical patent/PL2866797T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fencing (AREA)
PL12756353T 2012-07-06 2012-07-06 Stabilna, nadająca się do wstrzykiwania kompozycja farmaceutyczna antagonisty receptora neurokininy-1 i sposób jej wytwarzania PL2866797T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/002854 WO2014005606A1 (en) 2012-07-06 2012-07-06 Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof
EP12756353.4A EP2866797B1 (en) 2012-07-06 2012-07-06 Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof

Publications (1)

Publication Number Publication Date
PL2866797T3 true PL2866797T3 (pl) 2020-11-02

Family

ID=46826407

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12756353T PL2866797T3 (pl) 2012-07-06 2012-07-06 Stabilna, nadająca się do wstrzykiwania kompozycja farmaceutyczna antagonisty receptora neurokininy-1 i sposób jej wytwarzania

Country Status (14)

Country Link
US (2) US20150165045A1 (pl)
EP (1) EP2866797B1 (pl)
CY (1) CY1123370T1 (pl)
DK (1) DK2866797T3 (pl)
ES (1) ES2798103T3 (pl)
HR (1) HRP20201138T1 (pl)
HU (1) HUE051147T2 (pl)
LT (1) LT2866797T (pl)
PL (1) PL2866797T3 (pl)
PT (1) PT2866797T (pl)
RS (1) RS60599B1 (pl)
SI (1) SI2866797T1 (pl)
SM (1) SMT202000385T1 (pl)
WO (1) WO2014005606A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532660A (ja) 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
US20160324881A1 (en) * 2013-12-30 2016-11-10 Oncoprevent Gmbh Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
CA2956022A1 (en) * 2014-07-24 2016-01-28 Plus Vitech,S.L Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
US10610532B2 (en) * 2015-08-03 2020-04-07 Leiutis Pharmaceuticals Pvt. Ltd. Liquid formulations of fosaprepitant
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
KR20180118136A (ko) * 2016-02-01 2018-10-30 헤론 테라퓨틱스 인코포레이티드 Nk-1 수용체 길항제를 포함하는 에멀젼
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
HRP20200196T1 (hr) 2016-06-06 2020-05-01 Helsinn Healthcare Sa Fiziološki balansirane injektabilne formulacije fosnetupitanta
CN113288862B (zh) * 2016-08-03 2023-06-02 珠海贝海生物技术有限公司 含阿瑞吡坦的组合物及其制备方法和应用
EP3746051A1 (en) * 2018-01-30 2020-12-09 Heron Therapeutics, Inc. Method of administering emulsion formulations of an nk-1 receptor antagonist
US11654154B2 (en) 2019-01-29 2023-05-23 Navinta Iii Inc Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability
CN112168788B (zh) * 2019-07-01 2022-07-19 中国医学科学院药物研究所 静脉注射用阿瑞匹坦胶束无菌冻干制剂及其制备方法
CN110559255B (zh) * 2019-09-06 2022-08-19 南京医科大学 Zl006温敏凝胶及其制备方法
WO2023197637A1 (en) * 2022-04-14 2023-10-19 Wisdom Pharmaceutical Co., Ltd. Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection
CN115944745B (zh) * 2022-12-01 2024-03-22 石河子大学 一种具有聚集诱导发光性质的活性氧响应型药物控释体系及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
AU2005299748B2 (en) * 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
WO2007088483A1 (en) * 2006-02-03 2007-08-09 Glenmark Pahrmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
WO2007128056A1 (en) * 2006-05-03 2007-11-15 Cnsbio Pty Ltd Methods and composition for treatment of inflammatory pain
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2134327A1 (en) * 2007-03-13 2009-12-23 Sandoz AG Pharmaceutical compositions of poorly soluble drugs
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도
EP2451274B1 (en) * 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation

Also Published As

Publication number Publication date
CY1123370T1 (el) 2021-12-31
SI2866797T1 (sl) 2020-08-31
EP2866797B1 (en) 2020-04-29
SMT202000385T1 (it) 2020-11-10
HRP20201138T1 (hr) 2020-10-30
US20150165045A1 (en) 2015-06-18
WO2014005606A1 (en) 2014-01-09
EP2866797A1 (en) 2015-05-06
PT2866797T (pt) 2020-07-22
US20200237920A1 (en) 2020-07-30
HUE051147T2 (hu) 2021-03-01
LT2866797T (lt) 2020-06-25
RS60599B1 (sr) 2020-08-31
ES2798103T3 (es) 2020-12-09
DK2866797T3 (da) 2020-08-03

Similar Documents

Publication Publication Date Title
SI2866797T1 (sl) Stabilni injekcijski farmacevtski sestavek antagonista neurokinin 1 receptorja in postopek za njegovo pripravo
SMT202100166T1 (it) Derivati di 2, 2-difluoropropionammide di bardoxolone metile, composizioni farmaceutiche e loro polimorfi per l'uso nel trattamento di determinate condizioni
IL230218A (en) Converted atherothecyclic compounds, their preparations and their pharmaceutical preparations
IL214572A (en) Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease
PL2940014T3 (pl) Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna
BR112013015622A2 (pt) métodos de produção de composições farmacêuticas de dosagem sólida estabilizadas contendo morfinanos
IL228506A (en) Opioid receptor ligands and pharmacy preparations containing them
ZA201400501B (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
ZA201406145B (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
BR112013017169A2 (pt) composições farmacêuticas de ferro para administração oral
IL230463A0 (en) Benzamides, their preparation and pharmaceutical preparations containing them
ZA201407777B (en) High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
ZA201405959B (en) Novel neurokinin 1 receptor antagonist compounds
PL2773348T3 (pl) Kompozycja farmaceutyczna omeprazolu
IL231505A0 (en) Pharmaceutical preparation and method for its production
ZA201309359B (en) Compositions for sequential administration of opioid receptor agonists
PL394169A1 (pl) Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
SI2906555T1 (sl) Postopek za pripravo vorikonazola in njegovih analogov
FR2992218B1 (fr) Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
ZA201205978B (en) Solid pharmaceutical composition for buccal administration of agomelatine
ZA201300444B (en) Stable injectable pharmaceutical composition of vitamin d receptor agonist and process for preparation thereof
IL234614B (en) Pharmaceutical composition and preparation method thereof
ZA201105801B (en) Pharmaceutical composition containing leukotriene receptor antagonist and method for the preparation thereof